$172 Million is the total value of Medicxi Ventures Management (Jersey) Ltd's 5 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PHAT | PHATHOM PHARMACEUTICALS INC | $68,694,000 | -9.4% | 2,067,861 | 0.0% | 39.92% | +10.3% | |
| PCVX | VAXCYTE INC | $50,150,000 | -46.2% | 1,887,478 | 0.0% | 29.14% | -34.5% | |
| MRUS | MERUS N V | $28,048,000 | +46.1% | 1,600,000 | 0.0% | 16.30% | +77.8% | |
| CMPI | CHECKMATE PHARMACEUTICALS IN | $21,910,000 | +26.8% | 1,501,716 | 0.0% | 12.73% | +54.3% | |
| OBSV | OBSEVA SA | $3,266,000 | -16.1% | 1,570,000 | 0.0% | 1.90% | +2.1% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Francesco De Rubertis #1
- Kevin Stuart Johnson #2
- Michele Ollier #3
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PHATHOM PHARMACEUTICALS INC | 16 | Q3 2023 | 69.8% |
| MERUS N V | 16 | Q3 2023 | 25.3% |
| VAXCYTE INC | 14 | Q3 2023 | 44.5% |
| OBSEVA SA | 12 | Q3 2022 | 5.7% |
| CENTESSA PHARMACEUTICALS PLC | 10 | Q3 2023 | 71.3% |
| AURA BIOSCIENCES INC | 8 | Q3 2023 | 22.9% |
| CHECKMATE PHARMACEUTICALS IN | 8 | Q2 2022 | 12.7% |
| NEWAMSTERDAM PHARMA COMPANY | 4 | Q3 2023 | 11.4% |
| SYNTHORX INC | 1 | Q4 2019 | 43.1% |
View Medicxi Ventures Management (Jersey) Ltd's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-15 |
| 13F-HR | 2024-02-01 |
| 3 | 2024-01-26 |
| 13F-HR | 2023-10-18 |
| 13F-HR | 2023-07-19 |
| 13F-HR | 2023-04-27 |
| 13F-HR | 2023-01-31 |
| 13F-HR | 2022-10-25 |
| 13F-HR/A | 2022-08-03 |
| 13F-HR | 2022-08-03 |
View Medicxi Ventures Management (Jersey) Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.